{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:36:25Z","timestamp":1772829385729,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109929","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T02:17:33Z","timestamp":1677118653000},"page":"109929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation"],"prefix":"10.1016","volume":"117","author":[{"given":"Li","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Gilham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie C.","family":"Stotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Sarsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke D.","family":"Rakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Wasiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan O.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman C.W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewelina","family":"Kulikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.109929_b0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109929_b0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41556-021-00821-8","article-title":"BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2","volume":"24","author":"Samelson","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.intimp.2023.109929_b0015","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.109929_b0020","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","article-title":"SARS-CoV-2 variants and ending the COVID-19 pandemic","volume":"397","author":"Fontanet","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.109929_b0025","doi-asserted-by":"crossref","unstructured":"M.A. Tortorici, M. Beltramello, F.A. Lempp, D. Pinto, H. V Dang, L.E. Rosen, M. McCallum, J. Bowen, A. Minola, S. Jaconi, F. Zatta, A. De Marco, B. Guarino, S. Bianchi, E.J. Lauron, H. Tucker, J. Zhou, A. Peter, C. Havenar-Daughton, J.A. Wojcechowskyj, J.B. Case, R.E. Chen, H. Kaiser, M. Montiel-Ruiz, M. Meury, N. Czudnochowski, R. Spreafico, J. Dillen, C. Ng, N. Sprugasci, K. Culap, F. Benigni, R. Abdelnabi, S.-Y.C. Foo, M.A. Schmid, E. Cameroni, A. Riva, A. Gabrieli, M. Galli, M.S. Pizzuto, J. Neyts, M.S. Diamond, H.W. Virgin, G. Snell, D. Corti, K. Fink, D. Veesler, Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms., Science (New York, N.Y.). 370 (2020) 950\u2013957. https:\/\/doi.org\/10.1126\/science.abe3354.","DOI":"10.1126\/science.abe3354"},{"issue":"2020","key":"10.1016\/j.intimp.2023.109929_b0030","first-page":"915","article-title":"A potently neutralizing antibody protects mice against SARS-CoV-2 infection","volume":"205","author":"Alsoussi","year":"1950","journal-title":"J. Immunol. (Baltimore, Md."},{"key":"10.1016\/j.intimp.2023.109929_b0035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.109929_b0040","doi-asserted-by":"crossref","unstructured":"J. Zhang, T. Xiao, Y. Cai, C.L. Lavine, H. Peng, H. Zhu, K. Anand, P. Tong, A. Gautam, M.L. Mayer, R.M.J. Walsh, S. Rits-Volloch, D.R. Wesemann, W. Yang, M.S. Seaman, J. Lu, B. Chen, Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant., Science (New York, N.Y.). 374 (2021) 1353\u20131360. https:\/\/doi.org\/10.1126\/science.abl9463.","DOI":"10.1126\/science.abl9463"},{"key":"10.1016\/j.intimp.2023.109929_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.830527","article-title":"Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies","volume":"12","author":"Shah","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109929_b0050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41467-022-28528-w","article-title":"Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.109929_b0055","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMc2107799","article-title":"Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants","volume":"385","author":"Edara","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109929_b0060","doi-asserted-by":"crossref","unstructured":"N. Andrews, J. Stowe, F. Kirsebom, S. Toffa, T. Rickeard, E. Gallagher, C. Gower, M. Kall, N. Groves, A.-M. O\u2019Connell, D. Simons, P.B. Blomquist, A. Zaidi, S. Nash, N. Iwani Binti Abdul Aziz, S. Thelwall, G. Dabrera, R. Myers, G. Amirthalingam, S. Gharbia, J.C. Barrett, R. Elson, S.N. Ladhani, N. Ferguson, M. Zambon, C.N.J. Campbell, K. Brown, S. Hopkins, M. Chand, M. Ramsay, J. Lopez Bernal, Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant., The New England Journal of Medicine. 386 (2022) 1532\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa2119451.","DOI":"10.1056\/NEJMoa2119451"},{"key":"10.1016\/j.intimp.2023.109929_b0065","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jpclett.2c00912","article-title":"Immune escape mechanisms of SARS-CoV-2 delta and omicron variants against two monoclonal antibodies that received emergency use authorization","volume":"13","author":"Xiong","year":"2022","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.intimp.2023.109929_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.700926","article-title":"RIG-I-like receptor-mediated recognition of viral genomic RNA of severe acute respiratory syndrome coronavirus-2 and viral escape from the host innate immune responses","volume":"12","author":"Kouwaki","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.109929_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9091820","article-title":"TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection","volume":"9","author":"Bortolotti","year":"2021","journal-title":"Microorganisms."},{"key":"10.1016\/j.intimp.2023.109929_b0080","doi-asserted-by":"crossref","first-page":"e1008737","DOI":"10.1371\/journal.ppat.1008737","article-title":"Interplay between SARS-CoV-2 and the type I interferon response","volume":"16","author":"Sa Ribero","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2023.109929_b0085","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2023.109929_b0090","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.109929_b0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.109929_b0100","doi-asserted-by":"crossref","first-page":"eabd1554","DOI":"10.1126\/sciimmunol.abd1554","article-title":"Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2023.109929_b0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41590-021-01104-y","article-title":"Pathological sequelae of long-haul COVID","volume":"23","author":"Mehandru","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.109929_b0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41590-021-01113-x","article-title":"Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection","volume":"23","author":"Phetsouphanh","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.109929_b0115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109929_b0120","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.109929_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081126","article-title":"Relevance of BET Family Proteins in SARS-CoV-2 Infection","volume":"11","author":"Lara-Ure\u00f1a","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2023.109929_b0130","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA","volume":"29","author":"Huang","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.intimp.2023.109929_b0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/med.21730","article-title":"Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases","volume":"41","author":"Kulikowski","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.intimp.2023.109929_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113230","article-title":"Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators","volume":"152","author":"Tsujikawa","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2023.109929_b0145","doi-asserted-by":"crossref","unstructured":"K.K. Ray, S.J. Nicholls, K.A. Buhr, H.N. Ginsberg, J.O. Johansson, K. Kalantar-Zadeh, E. Kulikowski, P.P. Toth, N. Wong, M. Sweeney, G.G. Schwartz, Bet.I. and Committees, Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial, Jama. (2020). https:\/\/doi.org\/10.1001\/jama.2020.3308 [doi].","DOI":"10.1001\/jama.2020.3308"},{"key":"10.1016\/j.intimp.2023.109929_b0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40256-018-0298-8","article-title":"The Effect of bromodomain and extra-terminal inhibitor apabetalone on attenuated coronary atherosclerotic plaque: insights from the ASSURE trial","volume":"19","author":"Shishikura","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.intimp.2023.109929_b0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","article-title":"Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease","volume":"18","author":"Nicholls","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.intimp.2023.109929_b0160","doi-asserted-by":"crossref","unstructured":"K. Kalantar-Zadeh, G.G. Schwartz, S.J. Nicholls, K.A. Buhr, H.N. Ginsberg, J.O. Johansson, E. Kulikowski, K. Lebioda, P.P. Toth, N. Wong, M. Sweeney, K.K. Ray, on behalf of the Bet. Investigators, Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome, Clinical Journal of the American Society of Nephrology. 16 (2021) 705 LP \u2013 716. https:\/\/doi.org\/10.2215\/CJN.16751020.","DOI":"10.2215\/CJN.16751020"},{"key":"10.1016\/j.intimp.2023.109929_b0165","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1164\/rccm.202109-2182LE","article-title":"BET protein inhibition for pulmonary arterial hypertension: a pilot clinical trial","volume":"205","author":"Provencher","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2023.109929_b0170","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ekir.2017.12.001","article-title":"Benefit of apabetalone on plasma proteins in renal disease","volume":"3","author":"Wasiak","year":"2017","journal-title":"Kidney International Reports."},{"key":"10.1016\/j.intimp.2023.109929_b0175","first-page":"337","article-title":"Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208), Journal of Cardiovascular","volume":"10","author":"Wasiak","year":"2017","journal-title":"Transl. Res."},{"key":"10.1016\/j.intimp.2023.109929_b0180","doi-asserted-by":"crossref","first-page":"9397109","DOI":"10.1155\/2020\/9397109","article-title":"Epigenetic modulation by apabetalone counters cytokine-driven acute phase response in vitro, in mice and in patients with cardiovascular disease","volume":"2020","author":"Wasiak","year":"2020","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.intimp.2023.109929_b0185","doi-asserted-by":"crossref","unstructured":"L. Fu, S. Wasiak, L.M. Tsujikawa, B.D. Rakai, S.C. Stotz, N.C.W. Wong, J.O. Johansson, M. Sweeney, C.M. Mohan, A. Khan, E. Kulikowski, Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy, Pharmacology Research & Perspectives. 10 (2022) e00949. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/prp2.949.","DOI":"10.1002\/prp2.949"},{"key":"10.1016\/j.intimp.2023.109929_b0190","doi-asserted-by":"crossref","unstructured":"D. Gilham, L.M. Tsujikawa, C.D. Sarsons, C. Halliday, S. Wasiak, S.C. Stotz, R. Jahagirdar, M. Sweeney, J.O. Johansson, N.C.W. Wong, K. Kalantar-Zadeh, E. Kulikowski, Apabetalone downregulates factors and pathways associated with vascular calcification, Atherosclerosis. 280 (2019) 75\u201384. https:\/\/doi.org\/S0021-9150(18)31457-6 [pii].","DOI":"10.1016\/j.atherosclerosis.2018.11.002"},{"key":"10.1016\/j.intimp.2023.109929_b0195","doi-asserted-by":"crossref","first-page":"102-z","DOI":"10.1186\/s13148-019-0696-z","article-title":"Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism, Clinical","volume":"11","author":"Tsujikawa","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.intimp.2023.109929_b0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13148-020-00943-0","article-title":"BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes","volume":"12","author":"Wasiak","year":"2020","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.intimp.2023.109929_b0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2014.06.008","article-title":"A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice","volume":"236","author":"Jahagirdar","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.intimp.2023.109929_b0210","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.cell.2021.03.026","article-title":"BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection","volume":"184","author":"Mills","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.109929_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040437","article-title":"Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-Cov-2 infection in vitro","volume":"9","author":"Gilham","year":"2021","journal-title":"Biomedicines."},{"key":"10.1016\/j.intimp.2023.109929_b0220","doi-asserted-by":"crossref","first-page":"e83190","DOI":"10.1371\/journal.pone.0083190","article-title":"RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist","volume":"8","author":"McLure","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.109929_b0225","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12334","article-title":"Comprehensive evaluation of poly(I:C) induced inflammatory response in an airway epithelial model","volume":"3","author":"Lever","year":"2015","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.intimp.2023.109929_b0230","first-page":"74","article-title":"IFIT proteins are involved in CXCL10 expression in human glomerular endothelial cells treated with a toll-like receptor 3 agonist, kidney and blood pressure","volume":"46","author":"Imaizumi","year":"2021","journal-title":"Research"},{"key":"10.1016\/j.intimp.2023.109929_b0235","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1073858420939033","article-title":"COVID-19 pulmonary and olfactory dysfunctions: is the chemokine CXCL10 the common denominator?","volume":"27","author":"Oliviero","year":"2021","journal-title":"The Neuroscientist: Rev. J. Bring. Neurobiol. Neurol. Psychiat."},{"key":"10.1016\/j.intimp.2023.109929_b0240","doi-asserted-by":"crossref","unstructured":"C.N. Fran\u00e7a, M.C.O. Izar, M.N.S. Hort\u00eancio, J.B. do Amaral, C.E.S. Ferreira, I.D. Tuleta, F.A.H. Fonseca, Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease, Clinical Science (London, England\u00a0: 1979). 131 (2017) 1215\u20131224. https:\/\/doi.org\/10.1042\/CS20170009 [doi].","DOI":"10.1042\/CS20170009"},{"key":"10.1016\/j.intimp.2023.109929_b0245","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","article-title":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","volume":"146","author":"Copaescu","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2023.109929_b0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2023.109929_b0255","doi-asserted-by":"crossref","unstructured":"P. V\u2019kovski, A. Kratzel, S. Steiner, H. Stalder, V. Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, Nature Reviews Microbiology. 19 (2021) 155\u2013170. https:\/\/doi.org\/10.1038\/s41579-020-00468-6.","DOI":"10.1038\/s41579-020-00468-6"},{"key":"10.1016\/j.intimp.2023.109929_b0260","doi-asserted-by":"crossref","first-page":"10702","DOI":"10.1074\/jbc.M110.185793","article-title":"Raftlin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation","volume":"286","author":"Watanabe","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2023.109929_b0265","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1021\/ja111312h","article-title":"Small-molecule inhibitors of the TLR3\/dsRNA complex","volume":"133","author":"Cheng","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.intimp.2023.109929_b0270","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"A review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy: J. Human Pharmacol. Drug Therapy"},{"key":"10.1016\/j.intimp.2023.109929_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102477","article-title":"Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses","volume":"24","author":"Banerjee","year":"2021","journal-title":"IScience."},{"key":"10.1016\/j.intimp.2023.109929_b0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/acschembio.9b00810","article-title":"Small-molecule antagonists of the RIG-I innate immune receptor","volume":"15","author":"Rawling","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.intimp.2023.109929_b0285","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1152\/japplphysiol.00164.2004","article-title":"The anti-inflammatory effect of exercise","volume":"98","author":"Petersen","year":"2005","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.intimp.2023.109929_b0290","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12985-021-01633-w","article-title":"Evolutionary trajectory of SARS-CoV-2 and emerging variants","volume":"18","author":"Singh","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2023.109929_b0295","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJMc2209952","article-title":"Efficacy of antiviral agents against the omicron subvariant BA.2.75","volume":"387","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.109929_b0300","doi-asserted-by":"crossref","unstructured":"X. Deng, M.A. Garcia-Knight, M.M. Khalid, V. Servellita, C. Wang, M.K. Morris, A. Sotomayor-Gonz\u00e1lez, D.R. Glasner, K.R. Reyes, A.S. Gliwa, N.P. Reddy, C. Sanchez San Martin, S. Federman, J. Cheng, J. Balcerek, J. Taylor, J.A. Streithorst, S. Miller, B. Sreekumar, P.-Y. Chen, U. Schulze-Gahmen, T.Y. Taha, J.M. Hayashi, C.R. Simoneau, G.R. Kumar, S. McMahon, P. V Lidsky, Y. Xiao, P. Hemarajata, N.M. Green, A. Espinosa, C. Kath, M. Haw, J. Bell, J.K. Hacker, C. Hanson, D.A. Wadford, C. Anaya, D. Ferguson, P.A. Frankino, H. Shivram, L.F. Lareau, S.K. Wyman, M. Ott, R. Andino, C.Y. Chiu, Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant., Cell. 184 (2021) 3426-3437.e8. https:\/\/doi.org\/10.1016\/j.cell.2021.04.025.","DOI":"10.1016\/j.cell.2021.04.025"},{"key":"10.1016\/j.intimp.2023.109929_b0305","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1126\/science.adc9127","article-title":"Imprinted antibody responses against SARS-CoV-2 Omicron sublineages","volume":"378","author":"Park","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.109929_b0310","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.cell.2022.06.008","article-title":"Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation","volume":"185","author":"Fern\u00e1ndez-Casta\u00f1eda","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.109929_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.apsb.2020.10.006","article-title":"Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator","volume":"11","author":"Bian","year":"2021","journal-title":"Acta Pharm. Sin. B"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:55:45Z","timestamp":1761587745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923002497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":63,"alternative-id":["S1567576923002497"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109929","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109929"}}